Amanote Research
Register
Sign In
PHP118 Analysis of Pricing & Reimbursement Approval Process for New Drugs in Korea Under Newly-Introduced HTA Environment (2007-2010)
Value in Health
- United Kingdom
doi 10.1016/j.jval.2011.08.669
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
November 1, 2011
Authors
H.J. Kim
J.H. Park
H.H. Shin
S.K. Ko
Publisher
Elsevier BV
Related search
Reimbursement Decision Landscape for Orphan Drugs Across Six Hta Agencies
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency
Orphanet Journal of Rare Diseases
Medicine
Genetics
Pharmacology
Critical Analysis of Pricing and Reimbursement Process on the Basis of New Indroduced Pharmacoeconomic Guidelines in Bulgaria
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
FDA Approval of New Drugs
JAMA - Journal of the American Medical Association
Medicine
Pcp37 - The Confidentiality Regarding Drugs Pricing and Reimbursement in Romania
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Evaluation of Antihypertensive Drugs on the Reimbursement List for the Delisting Policy in Korea
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn25 - Role of Progression Free Survival in the Approval Process and European Hta Assessments
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php140 - Current Challenges and Potential Solution for Pricing Regulatory and Reimbursement Framework of Innovative Drugs in Egypt
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Analysis of Drug Pricing Under Conditions of Uncertainty of the Environment
Socìalʹna farmacìâ v ohoronì zdorov'â
